Clinical Trial

A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-26.
Status change: Not Yet Recruiting → Recruiting 2026-02-12
Trial Details
NCT Number NCT07327619
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Enrollment 420 participants
Start Date 2026-01-22
Primary Completion 2028-06 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-17